VKTX stock news

VKTX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-29 10:01:00 UTC#535942duplicateconfirmednews

Viking Therapeutics reports Q3 2026 net loss of $183.2M, EPS $(1.55) and clinical trial updates

tradingviewimportance 0.30trust 0.80Viking Therapeutics, Inc. -0.40VK2735 +0.20VANQUISH-1 +0.10+2 entities

2026-10-29 00:51:12 UTC#533600updateconfirmednews

Viking Therapeutics projects $100M average quarterly cash burn to support Phase III SUNRISE and VANQUISH trials

seeking alphaimportance 0.40trust 0.70Viking Therapeutics, Inc. -0.20

2026-10-28 23:20:12 UTC#533297updateconfirmednews

Viking Therapeutics advances VK2735 into four Phase III obesity studies with $960M in liquidity

quartrimportance 0.50trust 0.70Viking Therapeutics, Inc. +0.30VK2735 +0.40

2026-10-28 21:40:53 UTC#532873updateconfirmeddata release

Viking Therapeutics Q3 2026 adjusted loss of $1.55 per share misses analyst estimate of $1.07 loss

reutersimportance 0.60trust 0.90Viking Therapeutics, Inc. -0.60

2026-10-28 21:31:11 UTC#532763duplicateconfirmednews

Viking Therapeutics Q3 2026 net loss widens on increased R&D spending

seeking alphaimportance 0.30trust 0.70Viking Therapeutics, Inc. -0.30

2026-10-28 20:05:00 UTC#532020newconfirmedpress release

Viking Therapeutics reports Q3 2026 financial results and provides clinical updates on VK2735 and VK3019

pr newswireimportance 0.60trust 1.00Viking Therapeutics, Inc. 0VK2735 +0.40VK3019 +0.20

2026-10-27 11:00:45 UTC#520828newconfirmednews

Viking Therapeutics (VKTX) Q3 2026 earnings preview: analysts expect $0 revenue and $1.06 loss per share

tradingviewimportance 0.40trust 0.80Viking Therapeutics, Inc. -0.10

2026-10-21 20:05:00 UTC#495434newconfirmedpress release

Viking Therapeutics to report Q3 2026 financial results on October 28, 2026

pr newswireimportance 0.30trust 1.00Viking Therapeutics, Inc. 0

2026-10-14 11:05:00 UTC#458318newconfirmedpress release

Viking Therapeutics initiates Phase 3 clinical program for oral obesity drug VK2735

pr newswireimportance 0.70trust 1.00Viking Therapeutics, Inc. +0.60VK2735 +0.60SUNRISE-2 +0.40

2026-10-07 17:24:00 UTC#427284newconfirmednews

Truist Securities maintains Buy rating on Viking Therapeutics

dow_jonesimportance 0.30trust 0.60Viking Therapeutics, Inc. +0.20Truist Financial Corporation +0.20

2026-10-06 11:05:00 UTC#418843newconfirmedpress release

Viking Therapeutics initiates oral maintenance dosing clinical trial for obesity drug VK2735

pr newswireimportance 0.50trust 1.00Viking Therapeutics, Inc. +0.40VK2735 +0.40

2026-09-28 21:33:48 UTC#380468duplicateconfirmednews

Viking Therapeutics completes $547.8M equity and convertible note offering

tradingviewimportance 0.30trust 0.80Viking Therapeutics, Inc. -0.30Morgan Stanley 0JPMorgan Chase & Co. 0+2 entities

2026-09-28 20:30:00 UTC#380187duplicateconfirmedpress release

Viking Therapeutics closes $575M concurrent common stock and convertible note offering

pr_newswireimportance 0.40trust 1.00Viking Therapeutics, Inc. -0.20

2026-09-28 20:30:00 UTC#380179duplicateconfirmednews

Viking Therapeutics (VKTX) closes upsized $575M equity and convertible note offering

tradingviewimportance 0.30trust 0.80Viking Therapeutics, Inc. -0.20

2026-09-28 20:30:00 UTC#380135newconfirmedpress release

Viking Therapeutics closes upsized $575M common stock and convertible note offering

pr newswireimportance 0.50trust 1.00Viking Therapeutics, Inc. +0.20

2026-09-24 11:44:00 UTC#362038duplicateconfirmednews

Viking Therapeutics shares fall 12% after pricing upsized $500M stock and convertible notes offering

dow_jonesimportance 0.40trust 0.80Viking Therapeutics, Inc. -0.40

2026-09-24 11:29:19 UTC#361913duplicateconfirmednews

Viking Therapeutics prices upsized $500M offering of common stock and convertible senior notes

seeking alphaimportance 0.40trust 0.70Viking Therapeutics, Inc. -0.30

2026-09-24 11:09:09 UTC#361812duplicateconfirmednews

Viking Therapeutics prices upsized $500M offering of common stock and convertible notes

reutersimportance 0.30trust 0.90Viking Therapeutics, Inc. -0.30

2026-09-24 11:05:00 UTC#361759updateconfirmedpress release

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

pr newswireimportance 0.60trust 1.00Viking Therapeutics, Inc. -0.30

2026-09-23 21:14:47 UTC#358663duplicateconfirmedpress release

Viking Therapeutics confirms $400M capital raise via common stock and convertible notes due 2032

reutersimportance 0.40trust 0.90Viking Therapeutics, Inc. -0.40VK2735 0VK3019 0